Disease Overview：Polycystic Ovary Syndrome（PCOS）
Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder affecting 6–12% of women of reproductive age. Characterized by chronic anovulation, hyperandrogenism (e.g., hirsutism, acne, alopecia), and polycystic ovarian morphology on ultrasound, PCOS is associated with insulin resistance, metabolic dysfunction, and increased risk of type 2 diabetes, cardiovascular disease, and infertility. Diagnosis follows the Rotterdam criteria—requiring at least two of: oligo- or anovulation, clinical or biochemical signs of hyperandrogenism, and ultrasonographic evidence of polycystic ovaries—after excluding other etiologies such as thyroid dysfunction or hyperprolactinemia. Management is individualized and multidisciplinary, encompassing lifestyle modification, pharmacotherapy (e.g., metformin, combined oral contraceptives, ovulation-inducing agents like letrozole or gonadotropins), and assisted reproductive technologies (ART), including IUI and IVF, when fertility is desired.
China offers distinct advantages for PCOS-related reproductive care. Leading tertiary hospitals—many accredited by JCI or ISO—employ reproductive endocrinologists trained in both Western and integrative approaches, with extensive experience managing complex PCOS cases resistant to conventional therapy. Advanced ART platforms feature time-lapse embryo imaging, PGT-A, and personalized ovarian stimulation protocols optimized for PCOS patients to minimize OHSS risk. Clinical outcomes align with global benchmarks: live birth rates per fresh IVF cycle exceed 45% in top centers, supported by over a decade of published success data. Crucially, treatment costs—including diagnostics, medication, and IVF cycles—are typically 40–60% lower than in the US, UK, or Australia, without compromising quality or regulatory oversight.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: vetting accredited hospitals, coordinating consultations and treatment timelines, providing transparent, all-inclusive pricing (with no hidden fees), and offering end-to-end support—from visa assistance and accommodation to bilingual nursing coordination and post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Polycystic Ovary Syndrome (PCOS) — Reproductive Medicine Department
I. Non-Surgical / Conservative / Medication-Based Management
*Target criteria:* BMI < 35 kg/m², no severe insulin resistance or infertility refractory to first-line therapy, desire for ovulation induction or menstrual regulation.
- •Lifestyle Intervention (Mandatory First-Line)
- Baseline labs (fasting glucose, HbA1c, lipid panel, testosterone, SHBG, AMH): $110 - Pelvic ultrasound (transvaginal): $45
- •Pharmacotherapy (Tiered)
- Metformin (generic, 500 mg BID × 6 mo): $25 - COC (e.g., drospirenone/ethinyl estradiol): $35–$65 - *Tier 2 (Ovulation Induction):* Letrozole (3–6 cycles, monitored): - Letrozole (2.5 mg/day × 5 days/cycle × 4 cycles): $75 - Cycle monitoring (3 transvaginal ultrasounds + E2/P4 assays): $225 - *Tier 3 (Insulin Sensitization + Adjunct):* GLP-1 RA (semaglutide, 6 months, off-label but clinically used): $1,100–$1,450
II. Surgical / Procedural Interventions
*Eligibility:* Failed ≥6 months of letrozole/clomiphene + lifestyle; BMI ≤ 32 kg/m²; normal tubal patency confirmed; no contraindications to laparoscopy.
- •Laparoscopic Ovarian Drilling (LOD)
- Procedure (including OR time, anesthesia, pathology): $2,100–$2,800 - Post-op follow-up (2 visits + repeat ultrasound): $120
III. Special / Complex Condition Management
- •PCOS with Severe Obesity (BMI ≥ 35) + Infertility:
- •PCOS + Endometrial Hyperplasia (atypical):
- •PCOS + Type 2 Diabetes (HbA1c ≥ 9%):
IV. Quick Selection Guide
- •< 25 years, BMI < 28, mild hirsutism/menorrhagia: Start with lifestyle + COC ($290 total year-1)
- •25–35 years, infertility > 12 months, BMI 28–32: Letrozole + monitoring ($300/cycle, avg. 3 cycles = $900)
- •> 35 years, failed 6+ cycles, BMI ≤ 32: LOD ($2,500 median) — superior live birth rate vs. repeated IUI
- •BMI ≥ 35 + metabolic syndrome: Prioritize weight loss + GLP-1 RA ($1,300) before fertility intervention
- •Budget-constrained (< $500): Metformin + lifestyle only ($205) — effective for cycle regularization and metabolic improvement
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Polycystic Ovary Syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Polycystic Ovary Syndrome treatment with China top medical destinations:
